MCRB - Seres Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Seres Therapeutics, Inc.

200 Sidney Street
4th Floor
Cambridge, MA 02139
United States
617-945-9626
http://www.serestherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees138

Key Executives

NameTitlePayExercisedYear Born
Dr. Roger James Pomerantz M.D., F.A.C.P.Chairman, Pres & CEO967.13kN/A1957
Mr. Eric D. ShaffExec. VP, Chief Operating & Financial Officer and TreasurerN/AN/A1976
Dr. Michele TrucksisExec. VP & Chief Medical OfficerN/AN/A1953
Dr. John G. AuninsCTO and Exec. VP of Bioprocess & ManufacturingN/AN/A1961
Dr. David N. CookExec. VP of R&D and Chief Scientific OfficerN/AN/A1958
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company is also developing SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. In addition, its product candidates in pre-clinical development comprise SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; SER-401 for use with checkpoint inhibitors in patients with solid tumors; and SER-155, an Ecobiotic microbiome therapeutic candidate for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Seres Therapeutics, Inc.’s ISS Governance QualityScore as of September 1, 2018 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.